Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580122 | 0.81 | — | — | |
| SCHEMBL7995698 | 0.79 | — | — | |
| SCHEMBL28621275 | 0.76 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL301652 | 0.76 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL448747 | 0.72 | HDAC6 (0.34) | — | |
| SCHEMBL15177782 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL14183758 | 0.71 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL173228 | 0.70 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL11616346 | 0.70 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL7044812 | 0.70 | ALDH1A1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084645-B2 | 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20070105859-A1 | 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1674452-A1 | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND USE THEREOF AS MEK INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105859-A1 | 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors | MAPK9, MAPK4, MAPK1 | ALDH1A1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.